Positive allosteric modulators of α7 nAChRs (α7 PAMs) are emerging as potential therapeutics for a variety of pathologies, ranging from ulcerative colitis to AD, for their anti-inflammatory and pro-cognitive actions (183–185). Here, CHRNA7 is linked to ulcerative colitis.